Saturday 17 October 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.
24.17
0.44
−1.79%
Follow STOK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 32.64 |
+8 more quarters Free account |
P/S ratio |
78.30 | 64.01 | 10.19 | 6.70 | |
P/FCF ratio |
0.00 | 0.00 | 41.85 | 26.30 | |
P/Operating CF |
(38.17) | (33.89) | (61.72) | (45.36) | |
P/B ratio |
6.25 | 5.20 | 5.33 | 4.47 | |
Price to Tangible BV |
6.25 | 5.20 | 5.33 | 4.47 | |
EV/Sales |
67.68 | 53.30 | 8.65 | 5.49 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 40.73 | |
EV/Operating CF |
(10.49) | (11.65) | 34.99 | 21.37 | |
EV/FCF |
(10.33) | (11.58) | 35.51 | 21.56 | |
Quick Ratio |
7.19 | 8.57 | 5.06 | 6.21 | |
Current Ratio |
7.69 | 8.99 | 5.28 | 6.53 | |
Net Debt/EBITDA |
4.48 | 6.44 | 4.62 | 5.74 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.08 | 0.53 | 0.63 | |
Operating CF/Net income |
0.92 | 1.21 | 0.53 | 0.79 | |
Capex/Depreciation |
(22.20) | (4.77) | 1.59 | 0.76 | |
Research and Development Expense of Revenue |
530.84% | 636.91% | 2,973.97% | 354.55% | |
Selling, General and Administrative Expense of Revenue |
270.81% | 320.66% | 1,508.27% | 150.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
115.84% | 140.52% | 702.43% | 75.61% | |
Graham Net Nets |
0.13 | 0.16 | 0.13 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 9.23 | |
Earnings Yield |
(10.30%) | (8.72%) | (0.32%) | 3.06% | |
Free Cash Flow Yield |
(8.36%) | (7.19%) | 2.39% | 3.80% | |
Revenue per Share |
0.14 | 0.10 | 0.02 | 0.18 | |
Operating CF per Share |
(0.86) | (0.96) | (0.51) | (0.52) | |
Capex per Share |
(0.03) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.89) | (0.97) | (0.52) | (0.52) | |
Cash per Share |
4.44 | 5.45 | 4.81 | 4.24 | |
Shareholders Equity per Share |
5.23 | 6.26 | 5.95 | 5.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.23 | 6.26 | 5.95 | 5.26 | |
Free Cash Flow |
(58.56) | (60.93) | (30.69) | (30.50) | |
Working Capital |
280.61 | 325.88 | 247.83 | 230.71 | |
Capital Expenditures |
(1.98) | (0.35) | (0.23) | (0.13) | |
Net Current Asset Value |
274.12 | 318.28 | 239.72 | 220.28 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 41.52 | |
Capex to Sales |
0.21 | 0.06 | 0.17 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 50.65 | |
| Other line items | |||||
Average Receivables |
5.17 | 3.37 | 5.14 | 5.76 | |
Average Payables |
4.55 | 4.51 | 3.72 | 4.18 | |
Average Assets |
389.24 | 425.08 | 344.99 | 326.79 | |
Average Common Equity |
340.25 | 372.48 | 290.74 | 270.11 |
Columns are period end dates